Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics, Inc. (MLYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update – Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 – – New analyses from the pivotal Launch-HTN trial showed 46% of
How this was made
The 30-second read
Why it matters
The disclosed trial efficacy and upcoming PDUFA deadline provide a catalyst for price movement.
Market read
First‑report of pivotal trial data and financial results for a small‑cap biotech, likely to move the stock.
What to watch
Higher G&A spend and cash burn could pressure near‑term liquidity.
Mineralys reported a wider third-quarter net loss as commercialization spending increased ahead of the December 22, 2026 PDUFA target date for lorundrostat, while cash, cash equivalents and investments were $624.7 million.
Clinical and launch-readiness updates were positive, but G&A investment for commercialization drove a larger net loss and the company reported no revenue.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, three months ended September 30, 2026GAAP | $22.67M | – | – |
| General and administrative expenses, three months ended September 30, 2026GAAP | $37.42M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $60.09M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$60.09M | – | – |
| Interest and other income, three months ended September 30, 2026GAAP | $5.95M | – | – |
| Interest expense, three months ended September 30, 2026GAAP | −$3.19M | – | – |
| Total other income, net, three months ended September 30, 2026GAAP | $2.76M | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$57.33M | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, three months ended September 30, 2026GAAP | $ (0.64) | – | – |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted, three months ended September 30, 2026GAAP | 88,986,795 | – | – |
| Research and development expenses, nine months ended September 30, 2026GAAP | $268.4M | – | – |
| General and administrative expenses, nine months ended September 30, 2026GAAP | $83.06M | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | $351.5M | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | −$351.5M | – | – |
| Interest and other income, nine months ended September 30, 2026GAAP | $17.75M | – | – |
| Interest expense, nine months ended September 30, 2026GAAP | −$4.02M | – | – |
| Total other income, net, nine months ended September 30, 2026GAAP | $13.73M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$337.7M | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, nine months ended September 30, 2026GAAP | $ (3.95) | – | – |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted, nine months ended September 30, 2026GAAP | 85,538,811 | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Into 2028 outlook
- NoteThe Company believes that its current cash, cash equivalents and investments will be sufficient to fund planned operations, including the commercial launch of lorundrostat, into 2028.
What drove it
- R&D expenses decreased primarily due to $8.5 million of lower preclinical and clinical costs resulting from the conclusion of the lorundrostat pivotal program in the second quarter of 2025 and $0.3 million of decreased clinical supply, manufacturing, regulatory and other costs.
- G&A expenses increased primarily due to commercialization preparation, including $15.4 million in higher professional fees, $11.4 million in increased personnel-related expenses resulting from headcount growth and increased compensation, and $0.9 million of increased other administrative expenses.
- Total other income, net declined primarily due to $3.2 million of increased interest expense related to the senior secured term loan entered into in June 2026, partially offset by $1.8 million of increased interest earned on investments.
- The company reported an expanded medical affairs team and sales force in place, ongoing payer and physician engagement, brand marketing preparations, and a patient support program being finalized.
Concerns
- The company remains pre-revenue in the reported period and reported a net loss of $57.3 million for the quarter ended September 30, 2026.
- G&A expenses were $37.4 million for the quarter, driven by commercialization investments.
- Interest expense was $3.2 million for the quarter following entry into a senior secured term loan in June 2026.
- The FDA continues its review of the lorundrostat NDA, with a PDUFA target date of December 22, 2026.
What to watch
- The FDA review of the lorundrostat NDA and the December 22, 2026 PDUFA target date.
- Long-term efficacy and safety data from the ongoing Transform-HTN open-label extension trial, scheduled for late-breaking presentation at the American Heart Association Scientific Sessions 2026 on November 6-9 in Chicago, IL.
- Commercial-launch execution, including payer engagement, sales force deployment, brand marketing, and patient support program completion.
- The pace of commercialization-related G&A spending and cash use.
Balance sheet and cash flow
- Cash, cash equivalents and investments were $624.7 million as of September 30, 2026, compared to $656.6 million as of December 31, 2025.
- Total assets were $ 630,123 (in thousands) as of September 30, 2026, compared to $ 661,806 (in thousands) as of December 31, 2025.
- Senior secured term loan, net was $ 98,273 (in thousands) as of September 30, 2026, compared to $ — as of December 31, 2025.
- Total liabilities were $ 126,348 (in thousands) as of September 30, 2026, compared to $ 15,113 (in thousands) as of December 31, 2025.
- Total stockholders’ equity was $ 503,775 (in thousands) as of September 30, 2026, compared to $ 646,693 (in thousands) as of December 31, 2025.
Analysis
Mineralys remains a pre-commercial biopharmaceutical company, and its third-quarter results reflect preparation for a potential lorundrostat launch rather than product revenue. The company reported a GAAP net loss of $57.3 million for the quarter ended September 30, 2026, versus $36.9 million in the prior-year quarter. Loss from operations was $(60,087) (in thousands), compared with $(41,131) (in thousands) a year earlier. Net loss per share was $ (0.64), compared with $ (0.52), while weighted-average shares increased to 88,986,795 from 70,594,504.
Management, verbatim
With approximately 20 million adults in the U.S. living with uncontrolled or resistant hypertension, despite treatment, there is a significant need for new treatment options. As we approach the December 22nd PDUFA target date for lorundrostat, our focus is on completing our launch preparations so that we are ready to reach patients quickly, pending approval.
Jon Congleton, Chief Executive Officer of Mineralys
We also continue to highlight the data from our clinical trials in meetings with physicians and through presentations at scientific congresses, including our recent updates at AHA-HTN and ASN Kidney Week, and our upcoming presentation at the AHA Scientific Sessions. We continue to receive positive feedback from providers, payers and people living with hypertension, and we look forward to the potential to bring lorundrostat to millions of patients in need.
Jon Congleton, Chief Executive Officer of Mineralys
Not in the filing
stated, not guessed- Total revenue
- Segment revenue and segment operating metrics
- Gross profit and gross margin
- GAAP operating income
- Non-GAAP financial measures
- Operating cash flow
- Free cash flow
- Capital expenditures
- Repurchases and dividends
- Forward revenue guidance
- Forward gross-margin guidance
- Forward operating-expense guidance
- Forward tax-rate guidance
- Prior-quarter comparisons for reported operating metrics
- Percent year-over-year changes for reported operating metrics
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Mineralys Therapeutics (Nasdaq: MLYS) filed an 8‑K reporting Q3 2026 financials and new data from its lorundrostat trials.
Ticker impact
SEC 8‑K filing discloses Q3 2026 results and positive Phase 3 trial data for lorundrostat, a first‑report of material clinical outcomes.
likely upward pressure as investors price in efficacy data and upcoming FDA decision.
Trial results are new, statistically significant and directly tied to FDA review; biotech stocks typically react strongly to such data.
Market effects
Strengthens the hypertension‑therapy niche and may lift peer biotech valuations.
U.S. biotech sector could see modest gains.
Limited to investors focused on U.S. biotech pipelines.
Counterpoint
Trial endpoints are modest; FDA may request additional data, limiting upside.
Key entities
- companyMineralys Therapeutics, Inc.
Biopharma developing lorundrostat for hypertension.
- executiveJon Congleton
CEO of Mineralys, quoted on trial progress.
